OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Take (STAT)5: jazzing up T-cell leukemia
Pierluigi Porcu, Jason A. Dubovsky
Blood (2014) Vol. 124, Iss. 9, pp. 1383-1384
Open Access | Times Cited: 6
Pierluigi Porcu, Jason A. Dubovsky
Blood (2014) Vol. 124, Iss. 9, pp. 1383-1384
Open Access | Times Cited: 6
Showing 6 citing articles:
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janků, Timothy A. Yap, Funda Meric‐Bernstam
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 5, pp. 273-291
Closed Access | Times Cited: 897
Filip Janků, Timothy A. Yap, Funda Meric‐Bernstam
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 5, pp. 273-291
Closed Access | Times Cited: 897
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
Kumudha Balakrishnan, Marisa Peluso, Min Fu, et al.
Leukemia (2015) Vol. 29, Iss. 9, pp. 1811-1822
Open Access | Times Cited: 158
Kumudha Balakrishnan, Marisa Peluso, Min Fu, et al.
Leukemia (2015) Vol. 29, Iss. 9, pp. 1811-1822
Open Access | Times Cited: 158
Clinical Exome Sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: A pilot study in patients from the state of Qatar
Nader Al‐Dewik, Ben-Omran Tawfeg, Hatem Zayed, et al.
Gene (2018) Vol. 689, pp. 34-42
Closed Access | Times Cited: 24
Nader Al‐Dewik, Ben-Omran Tawfeg, Hatem Zayed, et al.
Gene (2018) Vol. 689, pp. 34-42
Closed Access | Times Cited: 24
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jacqueline C. Barrientos
Future Oncology (2016) Vol. 12, Iss. 18, pp. 2077-2094
Closed Access | Times Cited: 11
Jacqueline C. Barrientos
Future Oncology (2016) Vol. 12, Iss. 18, pp. 2077-2094
Closed Access | Times Cited: 11
Emerging immunological drugs for chronic lymphocytic leukemia
Paweł Robak, Piotr Smolewski, Tadeusz Robak
Expert Opinion on Emerging Drugs (2015) Vol. 20, Iss. 3, pp. 423-447
Closed Access | Times Cited: 10
Paweł Robak, Piotr Smolewski, Tadeusz Robak
Expert Opinion on Emerging Drugs (2015) Vol. 20, Iss. 3, pp. 423-447
Closed Access | Times Cited: 10
Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly
Anna Korycka, Dariusz Wołowiec, Tadeusz Robak
Expert Opinion on Drug Metabolism & Toxicology (2015) Vol. 11, Iss. 9, pp. 1371-1391
Closed Access | Times Cited: 7
Anna Korycka, Dariusz Wołowiec, Tadeusz Robak
Expert Opinion on Drug Metabolism & Toxicology (2015) Vol. 11, Iss. 9, pp. 1371-1391
Closed Access | Times Cited: 7
